Crossmark

Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

Crossref DOI link: https://doi.org/10.1007/s12325-022-02099-0

Published Online: 2022-03-12

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Agirrezabal, Ion https://orcid.org/0000-0003-3170-7845
Brennan, Victoria K. https://orcid.org/0000-0001-7814-2306
Colaone, Fabien https://orcid.org/0000-0002-9171-7861
Shergill, Suki https://orcid.org/0000-0001-5319-6770
Pereira, Helena https://orcid.org/0000-0001-7620-2467
Chatellier, Gilles https://orcid.org/0000-0002-6373-8956
Vilgrain, Valérie https://orcid.org/0000-0002-3568-7725
Funding

Funding for this research was provided by:

Sirtex Medical United Kingdom Ltd
License Information

Text and Data Mining valid from 2022-03-12

Version of Record valid from 2022-03-12
More Information

Article History

Received: 3 January 2022

Accepted: 15 February 2022

First Online: 12 March 2022